1Morkve O,Laerum OD.Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas[].Cytometry.1991
3Kroemer G, Petit P, Zamzami N, et al. The biochemistry of programmed cell death[J]. FASEB J, 1995, 9:1277- 1287.
4Wong CW, Lee A, Shientag L. Apoptosis: an early event in metastatic inefficiency[J]. Cancer Research, 2001, 61 ( 1 ):333-338.
5Toomey D, Smyth G, Condron C, et al. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features [ J]. Cancer, 2001,92:2648-2657.
6Lai RS, Wang JS, Hsu HK, et al. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer[J].Jpn Clin Oncol, 2002,32:393-297.
7Ludovini V, Gregorc V, Pistola L, et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer[ J]. Lung Cancer, 2004,46:77-85.
8Uchida S, Shimada Y, Watanabe G, et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis[ J]. Br J Cancer, 1998, 77:1704-1709.
9Porebska I, Wyrodek E, Kosacka M, et al. Apoptotic markers p53, bcl-2 and bax in primary lung cancer [ J ]. In vivo Greece, 2006,20 ( 5 ): 599-604.
10Puglisi F, Barbone F, Tell G, et al. Prognostic role of Ape/ Ref-1 subcellular expression in stage Ⅰ-Ⅲ breast carcinomas[J]. Oncol Rep,2002,9(1):11.
